Patents Assigned to Actelion Pharmaceuticals
-
Patent number: 11771683Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.Type: GrantFiled: November 5, 2020Date of Patent: October 3, 2023Assignee: Actelion Pharmaceuticals LtdInventors: Jasper Dingemanse, Matthias Hoch, Andreas Krause
-
Patent number: 11723896Abstract: The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.Type: GrantFiled: March 13, 2018Date of Patent: August 15, 2023Assignee: Actelion Pharmaceuticals LtdInventors: Martine Clozel, Laetitia Pouzol
-
Patent number: 11672783Abstract: The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E)but-2-ene-1,4-dioate, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 20, 2021Date of Patent: June 13, 2023Assignee: Actelion Pharmaceuticals LtdInventors: Martine Clozel, Luca Piali
-
Patent number: 11648249Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereofType: GrantFiled: December 9, 2020Date of Patent: May 16, 2023Assignee: Actelion Pharmaceuticals LtdInventors: Charles Tokunbo Adesuyi, Bruce Hamilton Lithgow, Olivier Lambert, Lovelace Holman
-
Publication number: 20230131600Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimmo)-3-o-tolyl-thiazolidin-4-one.Type: ApplicationFiled: October 13, 2022Publication date: April 27, 2023Applicant: ACTELION PHARMACEUTICALS LTDInventors: Jasper DINGEMANSE, Matthias HOCH, Andreas KRAUSE
-
Patent number: 11612600Abstract: The present invention relates to high doses of macitentan (INN), i.e. propylsulfamic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof, or of aprocitentan, for use in the treatment and/or prevention of chronic thromboembolic pulmonary hypertension (CTEPH). Moreover, the present invention relates to the use of high doses of macitentan or of aprocitentan for the manufacture of a medicament for the treatment and/or prevention of CTEPH, as well as to a method for the treatment and/or prevention of CTEPH comprising administering high doses of macitentan or of aprocitentan to a patient.Type: GrantFiled: May 4, 2022Date of Patent: March 28, 2023Assignee: Actelion Pharmaceuticals LtdInventors: Dénes Csonka, Wassim Fares, Hans Hoogkamer, Koen Torfs
-
Patent number: 11464777Abstract: The present invention relates to high doses of macitentan, i.e. propylsulfamic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof, or of aprocitentan, for use in the treatment and/or prevention of pulmonary arterial hypertension (PAH). Moreover, the present invention relates to the use of high doses of macitentan, or of aprocitentan, for the manufacture of a medicament for the treatment and/or prevention of PAH, as well as to a method for the treatment and/or prevention of PAH comprising high doses of macitentan or of aprocitentan. Further, the present invention relates to a dosage regimen for the treatment and/or prevention of PAH as well as to a combination of macitentan, or of aprocitentan, with one or more phosphodiesterase type 5 (PDE5) inhibitors, prostacyclin analogues, prostacyclin receptor agonists or soluble guanylate cyclase stimulators.Type: GrantFiled: October 29, 2021Date of Patent: October 11, 2022Assignee: Actelion Pharmaceuticals LtdInventors: Dénes Csonka, Wassim Fares, Hans Hoogkamer, Koen Torfs
-
Patent number: 11234980Abstract: The present invention relates to high doses of macitentan, i.e. propylsulfamic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof, or of aprocitentan, for use in the treatment and/or prevention of pulmonary arterial hypertension (PAH). Moreover, the present invention relates to the use of high doses of macitentan, or of aprocitentan, for the manufacture of a medicament for the treatment and/or prevention of PAH, as well as to a method for the treatment and/or prevention of PAH comprising high doses of macitentan or of aprocitentan. Further, the present invention relates to a dosage regimen for the treatment and/or prevention of PAH as well as to a combination of macitentan, or of aprocitentan, with one or more phosphodiesterase type 5 (PDE5) inhibitors, prostacyclin analogues, prostacyclin receptor agonists or soluble guanylate cyclase stimulators.Type: GrantFiled: March 2, 2021Date of Patent: February 1, 2022Assignee: Actelion Pharmaceuticals LtdInventors: Dénes Csonka, Wassim Fares, Hans Hoogkamer, Koen Torfs
-
Publication number: 20210401811Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.Type: ApplicationFiled: September 9, 2021Publication date: December 30, 2021Applicant: ACTELION PHARMACEUTICALS LTDInventors: Patrick BROSSARD, Jasper DINGEMANSE, Oliver NAYLER, Michael SCHERZ, Beat STEINER
-
Publication number: 20210338640Abstract: The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E)but-2-ene-1,4-dioate, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 20, 2021Publication date: November 4, 2021Applicant: ACTELION PHARMACEUTICALS LTDInventors: Martine CLOZEL, Luca PIALI
-
Patent number: 11136317Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.Type: GrantFiled: January 30, 2020Date of Patent: October 5, 2021Assignee: Actelion Pharmaceuticals LTDInventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
-
Publication number: 20210186966Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereofType: ApplicationFiled: December 9, 2020Publication date: June 24, 2021Applicant: ACTELION PHARMACEUTICALS LTDInventors: Charles Tokunbo ADESUYI, Bruce Hamilton LITHGOW, Olivier LAMBERT, Lovelace HOLMAN
-
Patent number: 11026927Abstract: The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E)but-2-ene-1,4-dioate, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 15, 2019Date of Patent: June 8, 2021Assignee: ACTELION PHARMACEUTICALS LTDInventors: Martine Clozel, Luca Piali
-
Patent number: 10946015Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof.Type: GrantFiled: February 20, 2018Date of Patent: March 16, 2021Assignee: ACTELION PHARMACEUTICALS LTDInventors: Charles Tokunbo Adesuyi, Bruce Hamilton Lithgow, Olivier Lambert, Lovelace Holman
-
Publication number: 20210052555Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.Type: ApplicationFiled: November 5, 2020Publication date: February 25, 2021Applicant: ACTELION PHARMACEUTICALS LTDInventors: Jasper DINGEMANSE, Matthias HOCH, Andreas KRAUSE
-
Patent number: 10857134Abstract: The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.Type: GrantFiled: January 29, 2019Date of Patent: December 8, 2020Assignee: ACTELION PHARMACEUTICALS LTDInventors: Jasper Dingemanse, Matthias Hoch, Andreas Krause
-
Publication number: 20200165235Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.Type: ApplicationFiled: January 30, 2020Publication date: May 28, 2020Applicant: ACTELION PHARMACEUTICALS LTDInventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
-
Patent number: 10660880Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.Type: GrantFiled: July 2, 2014Date of Patent: May 26, 2020Assignee: ACTELION PHARMACEUTICALS LTDInventors: Patrick Brossard, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
-
Patent number: 10603428Abstract: A device (1) for dispensing a fluid, in particular to a patient, comprising a container (15), in particular an at least partly collapsible container, with an interior (17) for receiving the fluid. The container (15) comprises a closure piece (20) which is rigidly arranged in the container (15) in particular and on which a dispensing opening (24) is formed, wherein the fluid can be dispensed out of the interior (17) through the dispensing opening. The device (1) comprises a pump device (40) driven by a pump drive (50) in order to pump the fluid out of the interior (17) of the container (15). The pump device (40) is fluidically arranged between the interior (17) and the dispensing opening (24) so that the fluid can be pumped out of the interior (17) to the dispensing opening (24) by the pump device (40).Type: GrantFiled: May 30, 2013Date of Patent: March 31, 2020Assignee: ACTELION PHARMACEUTICALS LTD.Inventor: Ludwig Daniel Weibel
-
Patent number: D974921Type: GrantFiled: March 22, 2021Date of Patent: January 10, 2023Assignee: Actelion Pharmaceuticals LtdInventors: Galina Gouvea, Paromita Sarkar